As Senseonics and Ascensia Diabetes Care looked for someone to help scale their CGM business, they turned to someone had only just retired. After close to eight years as Tandem Diabetes Care CCO, Brian Hansen notified the company of his decision to step down last August. His final day landed on Dec. 31, but he […]
ADA 2024
Embecta data highlights potential of insulin patch pumps for type 2 diabetes
Embecta (Nasdaq:EMBC) today shared new data highlighting the potential of an insulin patch pump in managing type 2 diabetes. Parsippany, New Jersey-based Embecta presented two abstracts at the American Diabetes Association Scientific Sessions in Orlando, Florida. The data pointed to the potential for adults with type 2 diabetes to better manage insulin delivery through a […]
Why Abbott acquired Bigfoot Biomedical and its smart insulin pens
When Abbott (NYSE:ABT) acquired Bigfoot Biomedical in September 2023, it took the final step to build upon a multi-year relationship. The medtech giant had a long-term, vested interest in Bigfoot, a maker of a smart insulin management system. It dates back to 2017, with Abbott even leading a financing round for Bigfoot in 2020. “We […]
Dexcom CEO explains plans for Stelo CGM, G7 and beyond
Dexcom (Nasdaq:DXCM) CEO Kevin Sayer says the prospect of an over-the-counter CGM made him and other company leaders uneasy. When the company first began planning a glucose monitor for the type 2 diabetes population not using insulin, there were questions about reimbursement, the impact of GLP-1 drugs and other causes for concern. “It made us […]
Sequel Med Tech’s unique twiist automated insulin delivery system brings something new to the space
Sequel Med Tech made significant waves when it announced the receipt of FDA clearance for an automated insulin delivery system in March. The company, founded just last year, brings significant expertise in a number of channels to the table, despite its short history. CEO Dr. Alan Lotvin co-founded Sequel, bringing decades of experience as an […]
Tandem Diabetes Care reports improved quality of life with Mobi automated insulin delivery system
Tandem Diabetes Care (Nasdaq:TNDM) today announced real-world insights highlighting user satisfaction with its Mobi automated insulin pump. San Diego-based Tandem launched Mobi, the world’s smallest, durable automated insulin delivery (AID) system in the U.S. this year. It received FDA clearance for people with diabetes ages six and up in July 2023. The system pairs with both the […]
MannKind’s inhaled insulin meets primary efficacy endpoint in study
MannKind today announced positive 17-week results from a Phase 4 U.S. clinical study of its Afrezza inhaled insulin powder. The Danbury, Connecticut-based company designed Afrezza, a rapid-acting inhaled human insulin, to improve glycemic control in adults with type 1 diabetes mellitus. The INHALE-3 study evaluated Afrezza against usual care — defined as multiple daily injections […]
Senseonics expects a Q4 launch for 365-day CGM, offers full-year outlook
Senseonics (NYSE:SENS) today shared its full-year financial outlook and laid out expectations for a new product launch this year. The Germantown, Maryland-based company said the FDA review of its next-generation, 365-day, once-per-week calibration Eversense implantable continuous glucose monitor (CGM) is advancing as planned. It expects the progress to enable 510(k) clearance in the near future […]
Medtronic data shows reduced diabetes burdens with MiniMed 780G
Medtronic (NYSE:MDT) today announced new study results highlighting the benefits of its MiniMed 780G automated insulin delivery system. New data shows how the system addresses hyperglycemia and nighttime burden to tackle the unique burdens and challenges of diabetes. Those include managing highs and meal-time management or carb-counting. The company said its latest data also mirrors […]
Insulet seeks expanded FDA nod for Omnipod 5 to include type 2 population, reports positive data
Insulet (Nasdaq:PODD) today announced positive results from a type 2 diabetes pivotal trial of its Omnipod 5 automated insulin delivery system. The company recently submitted its study results to the FDA for an expansion of Omnipod 5’s indications for use. It hopes to garner clearance for the type 2 diabetes population and launch in the […]
